ATOS (STOCKS)
Atossa Therapeutics, Inc. Common Stock
$2.550000
+0.200000 (+8.51%)
Prev close: $2.350000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Steven C. Quay
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $27.67M
- Employees
- 13
- P/E (TTM)
- -0.54
- P/B (TTM)
- 0.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.95 | $-1.05 | +0.0955 | +9.13% |
|
Mar 2026 (Q1)
|
$-1.11 | $-6.25 | +5.1358 | +82.23% |
|
Dec 2025 (Q4)
|
$-3.08 | $-1.16 | -1.9197 | -165.45% |
|
Sep 2025 (Q3)
|
$-1.05 | $-1.02 | -0.0299 | -2.93% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $39.25M |
| Research and Development | $21.20M |
| Other Operating Expenses | $18.05M |
| Operating Income/Loss | -$39.25M |
| Income/Loss From Continuing Operations After Tax | -$37.71M |
| Income/Loss From Continuing Operations Before Tax | -$37.71M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$37.71M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$37.71M |
| Net Income/Loss Available To Common Stockholders, Basic | -$37.71M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.99 |
| Diluted Earnings Per Share | -$5.99 |
| Basic Average Shares | 26,142,922 |
| Diluted Average Shares | 26,142,922 |
| Assets | $32.28M |
| Current Assets | $31.01M |
| Prepaid Expenses | $1.79M |
| Other Current Assets | $29.22M |
| Noncurrent Assets | $1.27M |
| Liabilities | $5.45M |
| Current Liabilities | $5.45M |
| Accounts Payable | $1.98M |
| Wages | $972.00K |
| Other Current Liabilities | $2.50M |
| Noncurrent Liabilities | $0.00 |
| Equity | $26.83M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $26.83M |
| Liabilities And Equity | $32.28M |
| Net Cash Flow From Operating Activities | -$35.77M |
| Net Cash Flow From Operating Activities, Continuing | -$35.77M |
| Net Cash Flow From Investing Activities | $15.19M |
| Net Cash Flow From Investing Activities, Continuing | $15.19M |
| Net Cash Flow From Financing Activities | $20.58M |
| Net Cash Flow From Financing Activities, Continuing | $20.58M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$37.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$37.71M |
| Other Comprehensive Income/Loss | $0.00 |